Anti-TNFα therapy and its implication in gynecology and obstetrics
Copyright © 2011 Elsevier Masson SAS. All rights reserved..
Anti-TNFα treatments have modified the medical care, the course and the quality of life of the patients with autoimmune rheumatic, cutaneous or bowel inflammatory diseases. On the other hand, these treatments may have potential severe side effects during pregnancy (congenital malformations, fetal infections). Actually, many pregnancies have been reported during anti-TNFα exposures, with good maternal and neonatal outcomes. The introduction or the discontinuation of these treatments will always have to be discussed with the specialist of the chronic disease and, ideally, during a preconceptional counselling. In gynecology, anti-TNFα drugs may offer a new safe and effective approach to treating patients with recurrent miscarriages or unexplained or failed in vitro fertilization cycles. On the other hand, these treatments significantly increase the risk for serious infections or viral reactivations and may promote gynaecological malignancies. An adapted gynaecological survey is necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal de gynecologie, obstetrique et biologie de la reproduction - 40(2011), 6 vom: 15. Okt., Seite 492-7 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Médicaments anti-TNFα (tumor necrosis factor α) en gynécologie et en obstétrique |
|---|
| Beteiligte Personen: |
Ducarme, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents |
|---|
| Anmerkungen: |
Date Completed 30.04.2012 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgyn.2011.05.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM20974488X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM20974488X | ||
| 003 | DE-627 | ||
| 005 | 20231224010354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.jgyn.2011.05.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0699.xml |
| 035 | |a (DE-627)NLM20974488X | ||
| 035 | |a (NLM)21733638 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Ducarme, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-TNFα therapy and its implication in gynecology and obstetrics |
| 246 | 3 | 3 | |a Médicaments anti-TNFα (tumor necrosis factor α) en gynécologie et en obstétrique |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2012 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2011 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Anti-TNFα treatments have modified the medical care, the course and the quality of life of the patients with autoimmune rheumatic, cutaneous or bowel inflammatory diseases. On the other hand, these treatments may have potential severe side effects during pregnancy (congenital malformations, fetal infections). Actually, many pregnancies have been reported during anti-TNFα exposures, with good maternal and neonatal outcomes. The introduction or the discontinuation of these treatments will always have to be discussed with the specialist of the chronic disease and, ideally, during a preconceptional counselling. In gynecology, anti-TNFα drugs may offer a new safe and effective approach to treating patients with recurrent miscarriages or unexplained or failed in vitro fertilization cycles. On the other hand, these treatments significantly increase the risk for serious infections or viral reactivations and may promote gynaecological malignancies. An adapted gynaecological survey is necessary | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 700 | 1 | |a Amate, P |e verfasserin |4 aut | |
| 700 | 1 | |a Seirafi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccaldi, P-F |e verfasserin |4 aut | |
| 700 | 1 | |a Bouhnik, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Luton, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal de gynecologie, obstetrique et biologie de la reproduction |d 1972 |g 40(2011), 6 vom: 15. Okt., Seite 492-7 |w (DE-627)NLM000005746 |x 1773-0430 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2011 |g number:6 |g day:15 |g month:10 |g pages:492-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgyn.2011.05.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2011 |e 6 |b 15 |c 10 |h 492-7 | ||